Koers ExpreS2ion Biotech Holding AB Nasdaq Stockholm
Aandelen
SE0008348262
Farmaceutische producten
Omzet 2024 * | 8 mln. 759K 694K | Omzet 2025 * | 8 mln. 759K 694K | Marktkapitalisatie | 85,3 mln. 8,09 mln. 7,4 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -25 mln. -2,37 mln. -2,17 mln. | Nettowinst (verlies) 2025 * | -37 mln. -3,51 mln. -3,21 mln. | EV/omzet 2024 * | 3,78 x |
Nettoliquiditeiten 2024 * | 55,05 mln. 5,22 mln. 4,78 mln. | Nettoliquiditeiten 2025 * | 14,16 mln. 1,34 mln. 1,23 mln. | EV/omzet 2025 * | 8,89 x |
K/w-verhouding 2024 * |
-2,66
x | K/w-verhouding 2025 * |
-1,82
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Bent Frandsen
CEO | Chief Executive Officer | - | 01-01-16 |
Keith Alexander
DFI | Director of Finance/CFO | 48 | 01-10-20 |
Max M. Søgaard
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jakob Knudsen
BRD | Director/Board Member | 56 | 01-04-17 |
Karin Garre
BRD | Director/Board Member | 67 | 26-05-21 |
Martin Jensen
FOU | Founder | 64 | 01-01-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,54% | 100 mld. | |
+11,97% | 43,89 mld. | |
-11,76% | 33,24 mld. | |
+79,59% | 29,36 mld. | |
-12,20% | 16,08 mld. | |
+4,00% | 14,68 mld. | |
-1,90% | 12,87 mld. | |
+178,17% | 10,55 mld. | |
+4,72% | 8,83 mld. |